Product Description
Mechanisms of Action: DNA Gyrase Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral, Inhalant
FDA Designation: *
Approval Status: Not Approved
Approved Countries: Austria | Bangladesh | Brazil | Dominican Republic | Hong Kong | India | Malaysia | Norway | Pakistan | Poland | South Africa
Approved Indications: None
Known Adverse Events: None
Company: Fraunhofer Institut
Company Location:
Company Founding Year: None
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT03575312 |
EnroHuman | N/A |
Completed |
Healthy Volunteers |
2018-06-04 |
2019-03-22 |
Treatments |